Targeting MUC21 could present an opportunity to enhance the effectiveness of immunotherapy and overcome resistance in NSCLC by circumventing the immune evasion mechanisms employed by cancer cells. The gene discussed is MUC21; the disease is non-small cell lung carcinoma.